Loading
Definium Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by GRYSKA DAVID W, was filed 05 Dec 2024.
Insider Decl.
162
Thresholds
n/a
Buy Volume
€41,471
4 ops. · all time
Sell Volume
€8M
74 ops. · all time
Who traded when
BuySaleRobert Barrow9 sales
Mark Sullivan8 sales
Daniel Karlin7 sales
Brandi Roberts2 sales
Liao Carrie2 sales
Matthew T. Wiley2 sales
+2 other insiders
Since the insiders bought
- +74.7%Entry US$7.44 · Close at T+365 US$13.00
- +53.2%Entry US$6.41 · Close at T+365 US$9.82
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Definium Therapeutics, Inc. Strong Buy (bullish), based on 18 analysts. Average price target: US$72.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$35.09
Analyst consensus
18 analystsStrong buy
US$55.00Target US$72.33(+106%)US$91.00
Income statement
EBITDA-US$178.3M
Net income-US$183.8M0.0% margin
Valuation
PER (forward)-18.1x
P/Book5.1x
Beta2.19
Balance sheet & cash
Market capUS$4.7B
Total debtUS$40.6M
Free Cash Flow-US$131.6M
Debt / Equity4%
Profitability & ownership
ROE-64.1%
ROA-20.6%
% insiders2.6%
% institutions88.4%
Last declaration on 29 September 2026
Declarations162 total
14,051 shares@ US$36.570.011% mcap72.6% of flowCommon SharesSEC:0001104659-26-112060:0
3,097 shares@ US$36.570.0023% mcap100.0% of flowCommon SharesSEC:0001104659-26-112061:0
10,853 shares@ US$36.570.0081% mcap73.2% of flowCommon SharesSEC:0001104659-26-112065:0
31,550 shares@ US$36.570.024% mcap50.1% of flowCommon SharesSEC:0001104659-26-112062:0
3,377 shares@ US$36.570.0025% mcap100.0% of flowCommon SharesSEC:0001104659-26-112058:0
31,550 shares@ US$36.730.027% mcap37.4% of flowCommonSEC144:0001950047-26-009813
10,853 shares@ US$36.730.0091% mcap48.5% of flowCommonSEC144:0001950047-26-009814
3,097 shares@ US$36.730.0026% mcap48.5% of flowCommonSEC144:0001950047-26-009816
3,377 shares@ US$36.730.0028% mcap49.4% of flowCommonSEC144:0001950047-26-009817
14,051 shares@ US$36.730.012% mcap48.5% of flowCommonSEC144:0001950047-26-009823
1,086 shares@ US$35.520.0009% mcap100.0% of flowCommon SharesSEC:0001193125-26-395892:0
1,629 shares@ US$35.520.0013% mcap100.0% of flowCommon SharesSEC:0001193125-26-395893:0
750,000 shares0Common SharesSEC:0001193125-26-389887:0
125,000 shares0Common SharesSEC:0001193125-26-389890:0
200,000 shares0Common SharesSEC:0001193125-26-389892:0
125,000 shares0Common SharesSEC:0001193125-26-389888:0
125,000 shares0Common SharesSEC:0001193125-26-389889:0
19,023 shares@ US$37.940.015% mcap61.6% of flowCommon SharesSEC:0001193125-26-384042:1
40,000 shares0Common SharesSEC:0001193125-26-384042:0
19,023 shares@ US$37.75140.015% mcap22.8% of flowCommonSEC144:0001950047-26-009064
62,500 shares0Common SharesSEC:0001193125-26-345836:0
62,500 shares0Common SharesSEC:0001193125-26-345837:0
100,000 shares0Common SharesSEC:0001193125-26-345838:0
375,000 shares0Common SharesSEC:0001193125-26-345839:0
62,500 shares0Common SharesSEC:0001193125-26-345835:0
25 of 162 declarations
About Definium Therapeutics, Inc.
Sales by Robert Barrow, Chief Executive Officer of Definium Therapeutics, Inc., top the record: EUR 1,157,605 on June 25, 2026, EUR 1,013,830 on September 25, 2026 and EUR 622,422 on September 3, 2026. He filed 45 times, including 30 sales and 2 purchases. In all, 74 sales weigh EUR 8.4 million (median EUR 34,600) against 4 purchases worth EUR 41,471 (median EUR 9,947), which is 5% purchases among open-market trades.
The purchases are tiny: David W. Gryska (Director) bought EUR 18,827 on August 23, 2024 and EUR 17,048 on December 5, 2024, and Robert Barrow EUR 2,846 on August 19, 2024. Between August 19 and August 23, 2024, 2 filers bought for EUR 24,422.
Read moreShow less
The record has 162 filings, published between January 19, 2022 and September 29, 2026, including 69 grants. Dan Karlin (Chief Medical Officer) has 21, Mark Sullivan (Chief Legal Officer) 16, and Daniel Karlin, under the same title, 12 more. The year 2026 already holds 54, against 17 in 2025. Filings appear a median of 1 day after the trade. This US healthcare company is worth USD 4.7 billion, with 2.6% of the capital held by insiders. The last twelve months hold 57 filings, of which 17 sales and no purchase.
